Theo Outlook
Gilead Sciences (GILD) presents a bullish investment case with a current price of $134.25, a market capitalization of $166.63 billion, trailing P/E ratio of 19.8, and diluted EPS TTM of $6.78. The company has demonstrated solid fundamentals, including quarterly earnings growth of 23.4% year-over-year and revenue TTM of $29.44 billion, supported by a forward P/E of 15.67 that suggests undervaluation relative to growth prospects. Analyst consensus leans positive with a target price of $157.43, backed by 5 strong buys and 17 buys.
Key catalysts include Gilead's leadership in antiviral therapies for HIV, hepatitis B/C, and influenza, with flagship products like Harvoni and Sovaldi driving revenue. Upcoming Q1 2026 earnings on April 23 (EPS estimate $1.86) could provide momentum, alongside potential pipeline advancements and market expansion in high-margin therapeutics. Quarterly revenue growth of 4.7% YOY underscores steady demand in core franchises.
Risks encompass patent expirations on key drugs, intense competition from biosimilars, and regulatory hurdles from the FDA, compounded by macroeconomic pressures on healthcare spending. However, Gilead's low beta of 0.374 offers defensiveness, diversified portfolio mitigates single-drug reliance, and robust EBITDA of $14.58 billion supports resilience. Investors with moderate risk tolerance can hedge via the 2.31% dividend yield.
Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.